Literature DB >> 22448133

Vesiculation from Pseudomonas aeruginosa under SOS.

Reshma Maredia1, Navya Devineni, Peter Lentz, Shatha F Dallo, Jiehjuen Yu, Neal Guentzel, James Chambers, Bernard Arulanandam, William E Haskins, Tao Weitao.   

Abstract

Bacterial infections can be aggravated by antibiotic treatment that induces SOS response and vesiculation. This leads to a hypothesis concerning association of SOS with vesiculation. To test it, we conducted multiple analyses of outer membrane vesicles (OMVs) produced from the Pseudomonas aeruginosa wild type in which SOS is induced by ciprofloxacin and from the LexA noncleavable (lexAN) strain in which SOS is repressed. The levels of OMV proteins, lipids, and cytotoxicity increased for both the treated strains, demonstrating vesiculation stimulation by the antibiotic treatment. However, the further increase was suppressed in the lexAN strains, suggesting the SOS involvement. Obviously, the stimulated vesiculation is attributed by both SOS-related and unrelated factors. OMV subproteomic analysis was performed to examine these factors, which reflected the OMV-mediated cytotoxicity and the physiology of the vesiculating cells under treatment and SOS. Thus, SOS plays a role in the vesiculation stimulation that contributes to cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22448133      PMCID: PMC3289957          DOI: 10.1100/2012/402919

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


1. Introduction

A Gram-negative bacterium, Pseudomonas aeruginosa has emerged as a prevalent nosocomial pathogen not only for hospital-acquired [1] and medical device-related infections [2, 3], but also for burn [4] and war-wound infections [5]. For such a wide spectrum of infections, the molecular pathogenesis is still incompletely understood. Mechanisms underlying the wide range of infections may entail the bacterial stress responses that help the microorganism to fit in new environments. The stress responses encompass the production of outer membrane vesicles (OMVs) in a process of vesiculation that occurs during all phases of growth of Gram-negative bacteria [6, 7]. OMVs also play a role in the pathogenesis as P. aeruginosa OMVs deliver multiple enzymes and virulence factors into the host cells [8]. Furthermore, bacteria produce OMVs in response to environmental and cellular stress factors [9-11], as vesiculation appears to increase survival of bacteria over stress. Environmental stress constitutes antibiotic treatments that have been found to affect vesiculation. Treatment of Shigella dysenteriae with mitomycin C, which activates the SOS response [12, 13], led to the increased level of Shiga toxin-associated OMV production [14] and toxin production [15]. Such stress-induced vesiculation seems to enhance survival, since the under-vesiculating mutants of Escherichia coli succumbed, whereas the overvesiculating mutants appeared more viable, when they were challenged with lethal envelope stressors [16]. With vesiculation identified as a bacterial stress response to environmental stimuli such as antibiotics, antibacterial treatment may aggravate the infections. Therefore, while mechanisms underlying vesiculation resulting from stress responses, especially the antimicrobial-triggered SOS response, remain poorly understood, it is imperative to investigate the connection so that effective intervention can be developed. The SOS response [17] is a transcriptional response, in which LexA controls at least 40 SOS genes in E. coli [18-20] and 15 in P. aeruginosa [21]. SOS is triggered when bacteria are treated with DNA damage antibiotics, such as the quinolone antibiotic ciprofloxacin used in this work. The quinolone antibiotics target the type II topoisomerases including DNA gyrase (topoisomerase II) and topoisomerase IV [22]. These enzymes play an essential role in controlling superhelix density of chromosomal DNA to facilitate replication, recombination, repair, and transcription [22, 23]. Inhibiting these enzymes by ciprofloxacin leads to DNA strand breaks, the SOS signals. The mechanisms of the SOS response in P. aeruginosa and E. coli share the following steps (Figure 1). In the absence of the SOS signals, LexA blocks the transcription of the SOS genes [17]. When the SOS signals are generated during replication inhibition, RecA coprotease senses the signals and binds to the single-stranded DNAs to assume an active conformation [24]. Activated RecA stimulates the autocatalytic cleavage of LexA [25]. Consequently, LexA repression of the SOS genes is dismissed by this cleavage. Such derepression induces the SOS genes, leading to activation of the SOS response. One of them, sulA, is induced to inhibit and delay cell division transiently, resulting in cell filamentation, a sign of the SOS response, until DNA damage is ameliorated by the SOS proteins. The SOS proteins are involved in chromosome recombination, replication, repair, and segregation [26, 27]. As cell division is affected during SOS and is involved in OMV biogenesis [28], vesiculation may be linked to SOS. With antimicrobial agents inducing SOS and vesiculation, this link is quite likely as both SOS and vesiculation enhance bacterial survival [16, 29]. The purpose of this study is to investigate this link with multiple analyses.
Figure 1

The bacterial SOS response. The response is triggered by DNA-damage antibiotics. This response is controlled by the RecA-LexA interplay, in which LexA represses the SOS genes. DNA damage activates RecA to simulate autocatalytic cleavage of LexA so that the SOS genes are depressed and expressed. X, the mutation rendering LexA noncleavable.

2. Materials and Methods

2.1. Bacterial Strains, Media, and Chemicals

P. aeruginosa PAO1 was obtained from the Pseudomonas Genetic Stock Center (strain PAO0001). The LexA noncleavable (lexAN) strain, gratefully from Dr. Floyd E. Romesberg, was constructed by the replacement of the catalytic serine of LexA with alanine as described in [21] so that the SOS regulon is repressed by lexAN in the presence of DNA damage. All the strains were grown at 37°C in Luria-Bertani (LB, purchased from Fisher Scientific) with 1-μg/mL ciprofloxacin (Sigma-Aldrich, minimal inhibitory concentrations or MIC = 0.125 μg/mL) as described before [21]. Experiments started with overnight cultures derived from the one-day-old single colonies grown on LB plates; experiments with colonies older than 3 days might not be reproducible.

2.2. Microscopic Analysis

Microscopy and measurement of cell length were performed as described [30, 31]. Briefly, the log-phase cells were fixed as described [30] and examined under a microscope (ZESS Axioshop 2 plus) equipped with CCD and computerized image analysis. The cell length was measured with NIH Image J. Significance levels (probability P values) in mean cell length were determined from a two-tailed Student's t-test.

2.3. OMV Extraction

Overnight cultures were diluted to the OD600 nm of 0.01 with 7 mL LB in a 25-mL flat-bottom glass tube. The subcultures were grown in a shaker at 37°C at the 250-rpm speed for 8 hrs. After the first two hours, ciprofloxacin was added to the subcultures to the final concentration of 1 μg/mL. OMVs were isolated by a standard method [32] with slight modifications. The cells in the subcultures were removed first by centrifugation at 10,000 rpm (12,000 g) for 10 minutes at 4°C and second by filtering the supernatant through a 0.2-μm filter. The filtered supernatant (6 mL) was ultracentrifuged in a fixed angle rotor (Ti-1270) for 3 hours at 4°C for 33,000 rpm (100,000 g). The supernatant was discarded, and the pellet was resuspended in 50 μL of phosphate buffered saline (PBS) by pipetting rather than by vortexing. The OMV samples could be stored at 4°C for 1 day for the macrophage assay and 3 days for proteomic analysis without losing activity.

2.4. Lipid Extraction and Quantification

The method was adopted from a protocol published previously [33] with slight modifications. The procedures included an extraction of the lipids with a mixture of methanol, chloroform, and water in a ratio of 2 : 2 : 0.8 (v/v). The OMV pellet collected after ultracentrifugation of the 7-mL cell-free culture was resuspended in 80 μL water in an eppendorf tube and then, to the OMV suspension, 200 μL methanol, and 200 μL chloroform were added and mixed. To the cell pellet, water was added to the final volume of 500 μL, and the cells were resuspended completely by vigorous vortexing. Then, an 80-μL volume of cell suspension was transferred to an effendorf tube and mixed with 200 μL methanol and 200 μL chloroform. After a 10-min vortexing, the sample was centrifuged for 10 min at 13,000 rpm at 4°C. The chloroform layer was transferred completely by gently inserting a pipette through the water-methanol phase and the interphase down to the bottom of the tube. To the tube containing the aquatic phases, 100 μL chloroform and 80 μL water were added and mixed by a vortexing. Centrifugation and chloroform layer transfer were repeated as above. The two fractions of chloroform layers were pooled; effort should be made to avoid losing any volumes of these fractions. For quantification, an empty eppendorf tube had been weighed, and then, the chloroform fractions were transferred to it and evaporated to dryness in a speed vac. The dry lipids were weighed, and the net weight was acquired by subtracting the tube weight.

2.5. Transmission Electron Microscope (TEM)

TEM was conducted according to a standard protocol [34] with modifications. A 10-μL volume of the OMV sample was placed on the lacey carbon film on 300-mesh copper grids. The grids were incubated at 25°C overnight. Then, they were negatively stained by 1% uranyl acetate (w/v, Sigma) for 20 seconds, washed three times with water, and air-dried. OMVs were examined on an Analytical Electron Microscope (JEOL JEM-2010F) with a Schottky field emission electron source. TEM was operated at accelerating voltage of 200 kV, with resolution at 0.1 nm lattice with 0.19 nm point-to-point, with magnification range from 2,0000x to 1,500,000x, with spot sizes of 2~5 nm at TEM mode, with EDS/NBD/CBD of 0.5~2.4 nm, and with specimen tilt at ±25 degrees (X, Y). Images were taken with a camera length of 80~2,000 mm and objective lens of Cs 0.5 mm and Cc 1.1 mm. For each sample, 5–10 images were recorded, and the diameter of each OMV was measured and compared for statistical significance as above.

2.6. Macrophage Cytotoxicity and MTT Assay

The indicated equal amount of OMVs (Figure 4) determined according to the OMV protein assay were suspended in DMEM medium and added into a 96-well plate which had been seeded with murine macrophage J774 cells (2 × 105/well). The plate was incubated at 37°C with 5% CO2 (v/v). The cytotoxicity was examined in the macrophage cytotoxicity assays as described previously [35] with modifications. The seeded macrophage was incubated with OMVs at the indicated concentrations. First, macrophage morphology was examined under a phase-contrast microscope with a 40-x lens [VZEISS AXIOVERT-200 with AXIOCAM camera equipped with CCD and computerized image analysis] after 0.5, 1, 2, 4, and 24 h. Approximately 10 fields were examined for each of duplicate wells. Second, the commercial kit (cyto 96 nonradioactive cytotoxicity kits from Promega) was used to measure OMV cytotoxicity to macrophage. The concept of this kit is to measure a stable cytosolic enzyme lactate dehydrogenase (LDH), which is released when macrophage cells are lysed. The released LDH then reacts with NAD, and protons are donated to NAD from LDH. The reducing NADH then reacts with MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] and formazan (red) forms. By measuring the optical density of formazan at the wavelength of 490-nm, the cytotoxicity was quantified. The cytotoxicity is defined as the percentage of OMV-inflicted LDH release in contrast to the sum of detergent-lysed maximal release (positive control) and spontaneous release (negative control). The assay was carried out by following the manufacturer's protocol. The experiment wells were assembled to contain the 20-μL OMV sample, the 80-μL medium (DMEM plus 10% FBS, v/v and the 2 × 105target cells J774 cells), and the OMV effectors. The following control wells were arranged. The wells for effecter spontaneous LDH release contained medium and OMVs. The wells for target cell spontaneous LDH release included only target cells (macrophage) and medium. The wells for target cell maximum LDH release carried medium, target cells, and the Lysis Solution. A 10-μL volume of the Lysis Solution (10x) per 100 μL of culture medium was added, and the mixture was incubated for 45 minutes before the supernatant was harvested. The wells for volume correction control contained only medium and lysis solution. The wells for culture medium background were used to correct phenol red and LDH activity that might be present in serum-containing culture medium. The 96-well plate then was incubated at 37°C with 5% CO2 (v/v) for 4 hours. After incubation, the supernatant (40–50 μL) from each well (except for the Maximal LDH release control) was transferred into a well in a new 96-well plate and mixed with the same volume of substrate (tetrazolium salt, light-sensitive, so operate in dark). The 96-wells plate was incubated in the dark for 30 minutes at the room temperatures, and the reaction was terminated by adding the stop solution. The optical density was measured at the 490-nm wavelength.
Figure 4

OMV-mediated macrophage cytotoxicity is SOS dependant. OMVs isolated from the wild-type (wt) and the LexA noncleavable (lexAN) cells as indicated were incubated with macrophage. Top: phase-contrast microscopy of macrophage incubated with OMVs at 1.3 μg/mL after a 1 hr incubation. Bar, 20 μm. Bottom: cytotoxicity was measured as the levels of released cytosolic lactate dehydrogenase after 4 hr incubation. It was set 0 for the macrophage-only control. OMV concentrations: grey, 1.3 μg/mL; doted, 0.65 μg/mL; blank, 0.325 μg/mL. (*P < 0.05, n = 4).

2.7. OMV Proteomic Analysis

The proteomic analysis was performed by following a standard method [36] with slight modifications. Specifically, the OMV proteins were fractionated by SDS-PAGE [37] (10%, w/v) and stained by Coomassie blue. The lanes in replicates containing the proteins were cut out, sliced into pieces (1 × 1 mm), and placed into Eppendorf tubes. The slices were subjected to in vitro proteolysis by trypsin as follows. The first step was SDS removal from the gel slices. A 100-μL volume of 25 mM NH4HCO3/50% acetonitrile (v/v, Fisher) was added to cover the gel slice. The mixture was vortexed for 10 minutes, and the supernatant was discarded. These steps were repeated until the gel became colorless. Acetonitrile (100%, v/v) was added to cover the gel slices, and the mixtures were incubated for a few minutes at room temperatures until the gel slices shrank and turned white. Acetonitrile in the gel slices was removed by spinning in a speed vacuum at room temperatures to complete dryness. The second step was reduction, alkylation, and proteolysis. For rehydration of the gel slices, an approximate 50-μL volume of 10-mM DTT (Sigma) in 25-mM NH4HCO3 was added to each tube to cover the gel slices followed by vortexing and brief spinning. The reagents were allowed to react with gel pieces at 56°C for 60 minutes, and the supernatant was discarded. A 40-μL volume of 55 mM iodoacetamide (Sigma) was added to the gel pieces, and the mixture was vortexed and then centrifuged briefly. The reaction was incubated in the dark for 30 min, and the supernatant was removed. The gels were washed in 100 μL (or enough to cover the gels) of 25-mM NH4HCO3/50% acetonitrile (v/v) followed by vortex and centrifugation for 5 min. A 200-μL volume of acetonitrile (100%, v/v) was added and removed as above. Trypsin (3 mg/mL, Promega) was added to just barely cover the gel pieces, and after a brief spinning, the mixture was incubated at 37°C for overnight. The third was extraction of peptides from the gel slices. The gel slices were centrifuged briefly, and the aquatic extract supernatant was collected into a 0.5-mL Eppendorf tube. To the gel pieces, a 30-μL volume of 0.1% formic acid (v/v, Burdic & Jacson) in 25-mM NH4HCO3 was added, followed by vortexing for 15 min and spinning briefly. The supernatant was harvested and pooled into the aquatic extract supernatant. The collected samples were then spun in a speed-vacuum to reduce the volume to approximately 10 μL (avoid complete dryness). The samples were stored at −20°C. Lastly, capillary liquid chromatography-tandem mass spectrometry (LC/MS/MS) was conducted at the RCMI Proteomics & Protein Biomarkers Cores to determine the peptides derived from the proteins in the gel slices. Capillary LC/MS/MS was performed with a linear ion trap tandem mass spectrometer (LTQ-XLS, ThermoFisher), where the top 7 eluting ions were fragmented by collision-induced dissociation. Proteins were identified by searching MS/MS spectra against the NCBI nonredundant protein database (version 20100306; 10551781 sequences and 3596151245 residues). A probability-based database searching algorithm (Mascot, Matrixscience) was followed as described previously [38] with modifications. Briefly, database search criteria include taxonomy, bacteria (eubacteria, 3035644 sequences); enzyme, trypsin; variable modifications, carbamidomethylation of cysteines and oxidation of methionines; mass values, monoisotopic; protein mass, unrestricted; peptide mass tolerance, ±1000 ppm; fragment mass tolerance, ±0.8 Da; max missed cleavages, three instrument type, ESI-TRAP; number of queries, 87976. Peptide score distribution: Ions score is −10 log (P), where P is the probability that the observed match is a random event. With the molecular weight search (MOWSE) peptide-mass database developed [39], the MOWSE scoring algorithm was used to calculate a score of each peptide entry. Briefly, the experimental mass values were searched across a calculated peptide mass database. Match of experimental mass values with calculated values were counted when the calculated value was in the range of a given mass tolerance of an experimental value. These matches were probability (P) based to ensure that the observed match is a random event. In a search for such random matches, the significance threshold was set for P to be ≤0.05, that is, a 1 in 20 chance of being a false positive. The matches were scored, based on the calculated P, that is, −10 log (P). The higher the score, the lower the P value. These ions scores were used to calculate protein score, which was the sum of the highest ions score for each distinct sequence. The proteins that were consistently detected in the replicates were counted. The inferred proteins were further categorized for functions and domains in amino acid sequences with the protein analysis software and with the published data. Functions and amino acid sequences were inferred by using http://www.uniprot.org/uniprot/O67077. Proteins with signal peptide were searched with http://www.signalpeptide.de/index.php?m=myproteinindex. Signal peptide in the proteins was predicted by using http://www.cbs.dtu.dk/services/SignalP/. Transmembrane domains were deduced with http://www.ch.embnet.org/software/TMPRED_form.html.

3. Results

3.1. Vesiculation Under Ciprofloxacin-Triggered SOS

The hypothesis concerning association of SOS with vesiculation was tested. The P. aeruginosa wild-type and the LexA noncleavable (lexAN) strains were treated with ciprofloxacin at 1 μg/mL. OMVs were extracted from these strains. The rationale for the antibiotic treatment was that this antibiotic was known to activate the SOS response in P. aeruginosa at 1 μg/mL, but SOS was noninducible in the lexAN strain [21]. Thus, testing of these strains with this drug would provide data relevant to SOS. When treated with the antibiotic, the wild-type cells became more filamented (cell length: 5.1 μm ± 1.2 and n = 169) than the lexAN cells (4.61 μm ± 1.2 and n = 89) (Figures 2(b) and 2(e), P < 0.0001). The significant cell filamentation is the manifestation of the SOS response [30, 40–43]. It is impossible to complement the lexAN mutant, because the lexAN phenotype is dominant; that is, in the lexAN background, the wild-type LexA would be cleaved, while the lexAN would remain not degraded during SOS. Besides, when both the wild-type and the lexAN cells were treated with ciprofloxacin at 1 μg/mL, lysed cells appeared imperceptible (<2%, n = 500), in contrast to treatment at 5 μg/mL (minimal bactericidal concentration, MBC = 3.25 μg/mL) that led to noticeable damaged and lysed cells (20%–30%, Figures 2(c) and 2(f)). With the growth conditions determined, OMVs were isolated by ultracentrifugation from the cell-free supernatants of the wild-type and the lexAN cultures shown in Figures 2(b) and 2(e). The presence of OMVs in the samples was confirmed with transmission electron microscopy (Figures 2(b) and 2(e) insets). The diameters of OMVs from both strains appeared similar (P = 0.2 and n = 70). Additionally, phage activity was not detected in the 1-μg/mL-drug-treated cell-free cultures and the OMV samples (data not shown). Hence, when the cells grew with the antibiotic at 1 μg/mL and produced OMVs, the likelihood of OMV contamination with the unrelated proteins from lysed cells appeared very small and was further addressed as below.
Figure 2

Microscopy of P. aeruginosa under the ciprofloxacininduced SOS response. The wild-type (PAO1) and the LexA noncleavable (lexAN) strains were grown in LB with shaking for 2 hrs, and then ciprofloxacin (CPX) was added (1 μg/mL). The culture continued for 6 hrs. (a) PAO1 without and (b) with CPX. (c) PAO1 with 5 μg/mL CPX. (d) lexAN without and (e) with CPX. (f) lexAN with 5 μg/mL CPX. Arrows in (c) and (f) show damaged and lysed cells. Cell bar, 5 μm. Inset (b) shows transmission electron microscopy of OMVs from the treated wild-type cultures. Inset (e) shows lexAN OMVs. OMV bar, 0.1 μm.

3.2. Increase in OMV Protein Levels under SOS

OMVs were quantified from the wild-type and the lexAN strains treated with ciprofloxacin at 1 μg/mL. Briefly, both the wild-type and LexA noncleavable strains were grown with ciprofloxacin at 1 μg/mL. Both strains exhibited similar growth behaviors in the absence and in the presence of ciprofloxacin (Figure 3(a)). Since OMV protein quantity appeared to reflect the levels of OMVs [44], the OMV levels were determined from the same volume of culture containing the equal number of cells (Figure 3(a) at 480 min) by using Bradford assay of OMV proteins. With the ciprofloxacin treatment, the level of the wild-type OMV proteins increased more than 100-fold, as compared to that without (*P < 0.0001, Figure 3(a)). While the level of OMV proteins from the treated lexAN strain went up versus that of the untreated (P < 0.01), it did not reach the wild-type level, displaying 33% reduction reproducibly below the wild-type level (*P < 0.05, Figure 3(a)). These results demonstrate that vesiculation is stimulated by the antibiotic treatment. The data with lexAN suggest that the stimulation is attributed by LexA-dependent and independent mechanisms. The LexA-dependent mechanism of OMV stimulation involves SOS. The OMV protein level in the wild-type strain, which increased above that of the lexAN strain, was suppressed in the lexAN strain. Namely, the levels were increased when the SOS repressor LexA was autocleaved in the wild-type strain during SOS [25], but when LexA was made noncleavable in the lexAN strain [21], further augmentation appeared to cease. Therefore, these OMV proteins increased in the wild type but suppressed in the lexAN strain were termed the SOS-related. The LexA-independent mechanism may account for the increased levels of OMV proteins from the lexAN mutant over those from the untreated. These proteins were accordingly termed the SOS independent. Yet, the level was lower than that of the SOS-induced wild type (Figure 3(a)). In conclusion, the OMV protein level is increased from the cells treated with the antibiotic, and SOS contributes to the additional augmentation.
Figure 3

OMV production from P. aeruginosa under the ciprofloxacin-induced SOS response. (a) Growth of the wild-type (PAO1) and the LexA noncleavable strains. Both strain were grown in LB with shaking for 2 hrs, and then ciprofloxacin (CPX) was added. The culture continued for 6 hrs. OMVs were isolated from the wild-type and the lexAN cells treated with or without ciprofloxacin (CPX). (b) Quantification of OMV proteins by Bradford (n = 7) and (c) OMV lipids by weight (n = 3). (*P < 0.05).

3.3. Increase in OMV Lipid Levels under SOS

It seemed possible that the proteins unrelated to OMVs but produced during SOS might be co-centrifuged with OMVs. This possibility was excluded by OMV lipid quantification. From OMV protein quantification, given the observation that the increase in the OMV protein level in the treated wild-type strain was suppressed in the treated lexAN strain (Figure 3(a)), we wanted to confirm the increase in vesiculation with the lipid assay. The lipids were extracted from OMVs and cells, and the total dry lipids were weighed as described previously [33]. The OMV lipids of the wild-type strain treated with ciprofloxacin were heavier than those of the lexAN strain (*P < 0.05, Figure 3(b)). In contrast, the weights of the total lipids from cells did not change significantly, irrespective of strains and treatment (P ≥ 0.1, data not shown). Thus, the OMV lipid mass increased for the treated wild type, and the augmentation was suppressed in the treated lexAN strain, the results consistent with the OMV protein quantification. This consistency ruled out the possibility of OMV contamination with unrelated proteins but supported the notion of SOS involvement in vesiculation, yet, the SOS-unrelated factors contributing to the increase cannot be excluded.

3.4. OMV-Mediated Macrophage Cytotoxicity under SOS

Since OMVs act as a virulence factor [8, 45] and the OMV levels increase during the antibiotic-induced SOS, we wanted to investigate whether OMVs from the SOS strains differentially aggravates cytotoxicity. OMVs isolated from the wild-type and the lexAN cultures, either treated as above with ciprofloxacin or without, were added to macrophage in equal amounts. The cytotoxicity was assessed as described previously [35]. First, macrophage morphology was examined after incubation with OMVs from the untreated wild-type bacterial cells for 0.5, 1, 2, 4, and 24 h. Morphology changes appeared in the first h (Figure 4 Upper). OMVs from the ciprofloxacin-treated wild-type and the mutant cells caused dramatic alterations in the morphology of the macrophage, including cell shrinkage, detachment, and lysis, when compared with OMVs from the untreated bacterial cells. In contrast, treatment of macrophage with ciprofloxacin at 1 μg/mL did not cause the cytotoxic morphology, the result excluding a possibility of ciprofloxacin-inflicted toxicity presumably caused by the drug-carrying OMVs. Second, the cytotoxicity was quantified. It is defined as the percentage of the OMV-inflicted LDH release from macrophage in the detergent-lysed maximal release from macrophage (OMVs or macrophage alone did not lead to a LDH-increase). As shown in Figure 4 (lower), the OMV-inflicted macrophage toxicity appeared concentration-dependent. Cytotoxicity by OMVs from the treated wild-type strain increased over 55% versus that by OMVs from the untreated (P < 0.05). These results indicate that the OMV-mediated cytotoxicity is stimulated by OMVs from the antibiotic-treated bacterial cells. However, this stimulated cytotoxicity was not observed in OMVs from the treated lexAN culture (P < 0.05). Therefore, LexA appeared to suppress the increased cytotoxicity.

3.5. OMV Subproteomic Analysis

Under the ciprofloxacin treatment, the increased levels of the OMV proteins, lipids and the OMV-mediated cytotoxicity in the wild-type strain appeared to be suppressed in the lexAN strain. Many interesting questions were raised from these results as to what OMV proteins would be LexA-suppressed and what would be cytotoxicity-related. To address them, we examined the OMV subproteomes from the treated wild-type and the lexAN strains. The rationale for targeting the two treated strains was the following. For the treated wild-type strains, the OMV protein level was increased but suppressed for the lexAN strain. Thus, comparison of the OMV subproteomic data obtained from the two treated strains would provide information relevant to LexA or SOS. The comparison could help sort out the OMV proteins: the LexA-related and ciprofloxacin-specific or SOS-unrelated OMV proteins. When bacteria are treated with a certain antibiotic, drug-specific proteins were previously observed, such as OMPs [46, 47] and OMV proteins [48], which are unrelated to SOS. Most likely, the ciprofloxacin-specific OMV proteins would be found in both the wild-type and the lexAN OMV subproteomes, whereas the LexA-related OMV proteins would be detected in the OMV subproteome of the wild-type strain where LexA is autocleaved. Experimentally, the OMV proteins from the antibiotic-treated wild-type and lexAN strains were characterized by the SDS-PAGE-based proteomic analysis (Figure 5). While small differences were observed in the OMV protein profiles for the treated wild-type and the lexAN strains (Figure 5), subtle distinctions were expected, based on LexA repression of gene expression, especially of the SOS regulons [18-21]. To unveil the differences, the in vitro trypsin proteolysis and capillary LC/MS/MS analysis was performed to determine the OMV proteins in the gel slices (Figure 5). The degraded peptide masses were determined and searched across the bacterial protein databases with the P < 0.05-based MOWSE scoring algorithm [39]. Totally, 145 proteins were identified in the OMV subproteomes from the treated wild-type and the lexAN strains (Tables 1–3). Many of the known OMV proteins, such as OstA (no. 1) [49] and OprE (no. 37) [50, 51], were detected in the wild-type OMVs (Figure 5 and Table 1), whereas GroEL (no. 75) [52] and OprF (no. 78) [50, 51] in both the wild-type and the lexAN OMVs (Table 2). Thus, the OMV subproteomes were confirmed to harbor some known OMV proteins. Moreover, with the SOS status of the wild-type and the lexAN strains used, the subproteomic analyses led to discovery and categorization of SOS- and cytotoxicity-related OMV proteins. The proteins detected only in OMVs from the drug-treated wild-type cells were termed the WT OMV proteins (74 proteins listed in Table 1 or 51% of 145). Since SOS was triggered in the wild type but repressed in the lexAN strain [21], the proteins produced during SOS were expected to emerge in the wild-type OMVs but not in the lexAN OMVs. These proteins were SOS-related. However, the proteins present in OMVs from both the treated wild-type and the lexAN strains were named the common OMV proteins (35 in Table 2 or 24%). The presence in both the OMV subproteomes implied that the appearance in OMVs was not affected by LexA; thus these proteins were called the SOS-unrelated. The OMV proteins present in OMVs from the lexAN cells alone were called the lexAN OMV proteins (36 in Table 3 or 26%). While the categorization provides insights into the antibiotic-stimulated vesiculation, it does not seem reconciled with the protein banding profiles that show slight differences in OMV proteins from the wild-type and the lexAN strains. The apparent discrepancy stems from the limited capacity of SDS-PAGE in resolving proteins with similar sizes in a certain band and inability to separate proteins of similar masses but of different pIs. For instance, when parallel bands in the wild-type and the lexAN OMV proteins were cut off for proteomic analysis, the subproteomic contents of the proteins carrying various pIs in one band were not completely identical to those in its counterpart (data not shown). Obviously, the OMV subproteomic analysis appears comprehensive, remedying the limitation of SDS-PAGE analysis.
Figure 5

The SDS-PAGE based proteomic analyses of OMV proteins from the SOS-induced and the un-induced cells. CPX, ciprofloxacin. N, LexA noncleavable; and wt, wild-type. Illustrated to the right were the proteins known to associate with OMVs, cytotoxicity, and SOS (See text and Tables for details).

Table 1

The WT OMV proteins.

Protein access IDProtein descriptionScorepIMassPredicted functionsMembrane domains
(1) gi∣15595792OstA precursor [P. aeruginosa PAO1]3665.41104207Organic solvent tolerance proteinSP, TM
(2) gi∣30525581ChaPs, heat-shock protein [Piscirickettsia salmonis]1744.7957310Protein folding, immunogenic proteinn, TM
(3) gi∣15595608PilJ [P. aeruginosa PAO1]1654.6572484Cell motility, twitching motilitySP, TM
(4) gi∣15597641Glycine dehydrogenase [P. aeruginosa PAO1]1335.68103853Degradation of glycinen, TM
(5) gi∣254236694OprC precursor, putative [P. aeruginosa C3719]1176.0279268Copper transport outer membrane porinSP, TM
(6) gi∣15599015SecF [P. aeruginosa PAO1]1154.8133021Protein translocationSP, TM
(7) gi∣15599417Fe(III)-pyochelin OM receptor precursor [P. aeruginosa PAO1]1075.8679943Siderophore-iron transmembrane transporter activitySP, TM
(8) gi∣309885Aspartate transcarbamoylase [P. aeruginosa PAO1]1026.1736521Pyrimidine biosynthesisn, n
(9) gi∣83718562Peptide synthetase-like protein [Burkholderia thailandensis E264]965.91349402Peptide synthesisn, TM
(10) gi∣152986344YaeT [P. aeruginosa PA7]945.0288222OMP assembly complexSP, TM
(11) gi∣124022818Phosphate binding protein [Prochlorococcus marinus str. MIT 9303]909.5118989ABC transportSP, TM
(12) gi∣167840097Phospholipase D [Burkholderia thailandensis MSMB43]88664431Lipid catalytic activityn, TM
(13) gi∣167035883TonB-dependent copper receptor [P. putida GB-1]875.7774399Copper receptorSP, TM
(14) gi∣28871621Polyribonucleotide nucleotidyltransferase [P. syringae pv. tomato str. DC3000]815.2074880mRNA degradationn, TM
(15) gi∣15600748ATP synthase subunit γ [P. aeruginosa PAO1]737.7031533ATP productionn,n
(16) gi∣70732441M48 family peptidase [P. fluorescens Pf-5]697.6628833Protein dagradationSP, TM
(17) gi∣50085971Acridine efflux pump [Acinetobacter sp. ADP1]676.36114705Efflux pumpn, TM
(18) gi∣15596751Cytochrome oxidase subunit (cbb3-type) [P. aeruginosa PAO1]669.4253073Electron transport chainn, TM
(19) gi∣119713613SecD [uncultured marine bacterium EB0_39H12]625.6367763Protein translocationn, TM
(20) gi∣7715581PspA [Streptococcus pneumoniae]614.7027305Pneumococcal surface protein An, n
(21) gi∣10945103PapA [P. aeruginosa]614.8771649Lipid metabolic processSP, TM
(22) gi∣121605556Catalase [Polaromonas naphthalenivorans CJ2]616.2654212Hydrogen peroxide catabolic processn, n
(23) gi∣94495248Rhizopine catabolism protein [Sphingomonas sp. SKA58]605.9138825Oxidation reductionn, TM
(24) gi∣116328093Zn-dependent hydrolase [Leptospira borgpetersenii serovar Hardjo-bovis L550]595.6730997Hydrolase activitySP, TM
(25) gi∣149378317PAS [Marinobacter algicola DG893]595.9757059Signal transducer activity, chemotaxisTM
(26) gi∣119356290Molybdate ABC transporter, ATPase subunit [Chlorobium phaeobacteroides DSM 266]599.2338876ABC transportn, n
(27) gi∣117619653Methyl-accepting chemotaxis transducer [P. stutzeri A1501]594.6758670Methyl-accepting chemotaxisSP, TM
(28) gi∣119899764MCP-domain-containing signal transduction protein [Azoarcus sp. BH72]595.8053615Signal transductionSP, TM
(29) gi∣887858DcrH [Desulfovibrio vulgaris str. Hildenborough]595.71104664Signal transductionSP, TM
(30) gi∣28869218Aerotaxis receptor [P. syringae pv. tomato str. DC3000]595.7056965Aerotaxisn, TM
(31) gi∣112004994Symbionin [Buchnera aphidicola]585.1357904Protein foldingn, TM
(32) gi∣15597430PslD, biofilm proteins [P. aeruginosa PAO1]588.6627891polysaccharide transmembrane transportSP, TM
(33) gi∣154253615Molybdenum cofactor biosynthesis protein C [Parvibaculum lavamentivorans DS-1]589.6416871Cofactor biosynthesisn, n
(34) gi∣15600235PilO [P. aeruginosa PAO1]575.0422805Cell motility, type 4 fimbrial biogenesisn, TM
(35) gi∣29830660Oxidoreductase [Streptomyces avermitilis MA-4680]575.0133162Electron transport chainn, TM
(36) gi∣108803685Bifunctional homocysteine S-methyltransferase [Rubrobacter xylanophilus DSM 9941]576.3365183Amino-acid biosynthesisn, TM
(37) gi∣15595488OprE precursor [P. aeruginosa PAO1]548.6749637Anaerobically-induced OM porinSP, TM
(38) gi∣121997032Glycolate oxidase iron-sulfur subunit [Halorhodospira halophila SL1]538.5543945Oxidation reductionn, n
(39) gi∣161508096Biotin-acetyl-CoA-carboxylase ligase [Lactobacillus helveticus DPC 4571]53937120Protein modification processn, n
(40) gi∣119773234GTPase EngB [Shewanella amazonensis SB2B]526.9724168Cell divisionn, n
(41) gi∣75764772FtsK [Bacillus thuringiensis serovar israelensis ATCC 35646]504.3340378Cell divisionSP, TM
(42) gi∣3237312FimV [P. aeruginosa PAO1]504.3398113Cell motility, twitching motilitySP, TM
(43) gi∣145588417Ferric uptake regulator family protein [Polynucleobacter necessarius subsp. asymbioticus QLW-P1DMWA-1]506.2917176Repressor of the iron transport operonn, n
(44) gi∣163846285Deoxyribose-phosphate aldolase [Chloroflexus aurantiacus J-10-fl]506.0827440Deoxyribonucleotide catabolic processn, n
(45) gi∣107099581Hypothetical+C448_01000594 [P. aeruginosa PACS2]2675.13101779UnknownUnknown
(46) gi∣15598924Hypothetical PA3729 [P. aeruginosa PAO1]2495.1875836Unknownn, TM
(47) gi∣15599685Hypothetical PA4489 [P. aeruginosa PAO1]1795.48167326Putative endopeptidase inhibitor activitySP, TM
(48) gi∣156932378Hypothetical ESA_00154 [Enterobacter sakazakii ATCC BAA-894]1674.8357278Protein foldingn, TM
(49) gi∣15596261Hypothetical PA1064 [P. aeruginosa PAO1]1165.3824157Unknownn, TM
(50) gi∣218890269Hypothetical PLES_15291 [P. aeruginosa LESB58]976.3428636UnknownSP, TM
(51) gi∣15595825Hypothetical PA0628 [P. aeruginosa PAO1]928.8035848Unknownn, n
(52) gi∣15600425Hypothetical PA5232 [P. aeruginosa PAO1]909.1138586Protein transporterSP, TM
(53) gi∣15596143Hypothetical PA0946 [P. aeruginosa PAO1]864.9336754UnknownSP, TM
(54) gi∣107103341Hypothetical PaerPA_01004410 [P. aeruginosa PACS2]849.0267631UnknownUnknown
(55) gi∣15599691Hypothetical PA4495 [P. aeruginosa PAO1]845.7924864UnknownSP, TM
(56) gi∣15600607Hypothetical PA5414 [P. aeruginosa PAO1]755.7622533UnknownSP, TM
(57) gi∣1162960Protein homologous to HI0366 in Haemophilus influenzae [P. aeruginosa PAO1]726.7722403UnknownSP, TM
(58) gi∣148980343Hypothetical VSWAT3_23674 [Vibrionales bacterium SWAT-3]594.8556161ChemotaxisSP, TM
(59) gi∣86146473Hypothetical MED222_12698 [Vibrio sp. MED222]594.7668870Signal transducer activityn, TM
(60) gi∣32266390Hypothetical HH0891 [Helicobacter hepaticus ATCC 51449]594.9952013Signal transducer activityn, n
(61) gi∣89893845Hypothetical DSY1099 [Desulfitobacterium hafniense Y51]595.0054148Signal transducer activityn, n
(62) gi∣18309647Hypothetical CPE0665 [Clostridium perfringens str. 13]594.9128888UnknownUnknown
(63) gi∣160938898Hypothetical CLOBOL_03792 [Clostridium bolteae ATCC BAA-613]594.7960828ChemotaxisSP, TM
(64) gi∣167772543Hypothetical ANACOL_03921 [Anaerotruncus colihominis DSM 17241]594.6671478Signal transducer activitySP, TM
(65) gi∣158334828Hypothetical AM1_1665 [Acaryochloris marina MBIC11017]594.5428589Unknownn, n
(66) gi∣146298741Hypothetical Fjoh_0980 [Flavobacterium johnsoniae UW101]588.90168226UnknownSP, TM
(67) gi∣126348240Conserved hypothetical [Streptomyces ambofaciens ATCC 23877]584.68123551UnknownUnknown
(68) gi∣162454210Hypothetical sce5933 [Sorangium cellulosum So ce 56]5610.0649450UnknownSP, TM
(69) gi∣159184340Hypothetical Atu0493 [Agrobacterium tumefaciens str. C58]568.8317570UnknownUnknown
(70) gi∣120536835Hypothetical Maqu_4123 [Marinobacter aquaeolei VT8]546.0236805Unknownn, n
(71) gi∣88800650Hypothetical MED297_05259 [Reinekea sp. MED297]535.0574044UnknownUnknown
(72) gi∣107103648Hypothetical PaerPA_01004718 [P. aeruginosa PACS2]528.9252714UnknownUnknown
(73) gi∣124385398Hypothetical BMA10229_A0995 [Burkholderia mallei NCTC 10229]525.665192Unknownn, n
(74) gi∣94986987Hypothetical LI0545 [Lawsonia intracellularis PHE/MN1-00]516.4311768Unknownn, n

TM: transmembrane domains; SP: signal peptide; pI: isoelectric point.

Table 3

The lexAN OMV proteins.

Protein access IDProtein descriptionScorepIMassPredicted functionsMembrane domains
(110) gi∣155992486,7-dimethyl-8-ribityllumazine synthase [P. aeruginosa PAO1]2995.6916403Riboflavin biosynthesisn, n
(111) gi∣14573303PilA [P. aeruginosa]1606.2315488Major pilin subunit of type IV pilin, TM
(112) gi∣15598049OprI precursor [P. aeruginosa PAO1]1327.908829OM lipid-anchor.SP, TM
(113) gi∣15596004AmpDh3 [P. aeruginosa PAO1]1295.8928703Peptidoglycan catabolic processn, n
(114) gi∣15599856Lipid A 3-O-deacylase [P. aeruginosa PAO1]1165.8718382Modification of lipid A of LPSSP, TM
(115) gi∣15596159DNA-binding stress protein [P. aeruginosa PAO1]1004.9617482Response to stress, iron ion homeostasisn, n
(116) gi∣15599000PilF [P. aeruginosa PAO1]756.6728520Type 4 fimbrial biogenesisSP, TM
(117) gi∣15596133LpxO2 [P. aeruginosa PAO1]729.9035737LPS biosynthesisn, TM
(118) gi∣15600371LysM domain/BON superfamily protein [P. aeruginosa PAO1]695.4515451Cleavage of septal peptidoglycan to allow cell separationn, n
(119) gi∣15598026HtpX [P. aeruginosa PAO1]657.0331573Heat shock protein, proteolysisSP, TM
(120) gi∣15600018Mg(2+) transport ATPase, P-type 2 [P. aeruginosa PAO1]635.8899987Magnesium-importing ATPase activityn, TM
(121) gi∣1559976450S ribosomal protein L21 [P. aeruginosa PAO1]629.8511646Protein synthesisn, n
(122) gi∣116620118HAD family hydrolase [Solibacter usitatus Ellin6076]575.3722870Phosphoglycolate phosphatase activityn, n
(123) gi∣21233204RhlB [Xanthomonas campestris pv. campestris str. ATCC 33913]519.2562279ATP-dependent RNA helicase unwinding of double stranded RNAn, n
(124) gi∣1559946330S ribosomal protein S7 [P. aeruginosa PAO1]5110.2417493Protein synthesisn, n
(125) gi∣73537822Twin-arginine translocation pathway signal [Ralstonia eutropha JMP134]509.3736128Protein export through the cytoplasmic membraneSP, TM
(126) gi∣71064880GltI [Psychrobacter arcticus 273-4]505.1135348ABC glutamate/aspartate transporterSP, n
(127) gi∣15596250HypotheticalPA1053 [P. aeruginosa PAO1]2799.6415639UnknownSP, TM
(128) gi∣15599835HypotheticalPA4639 [P. aeruginosa PAO1]989.4720723UnknownSP, TM
(129) gi∣15600165HypotheticalPA4972 [P. aeruginosa PAO1]865.9827836UnknownSP, TM
(130) gi∣15598227HypotheticalPA3031 [P. aeruginosa PAO1]834.928007UnknownSP, TM
(131) gi∣15598151HypotheticalPA2955 [P. aeruginosa PAO1]705.3523677UnknownSP, TM
(132) gi∣145635820HypotheticalCGSHiAA_01062 [Haemophilus influenzae PittAA]695.8556041Unknownn, n
(133) gi∣183222376Hypothetical LEPBI_I3030 [Leptospira biflexa serovar Patoc strain Patoc 1 (Paris)]618.4051147Transporter activitySP, TM
(134) gi∣57233652HypotheticalDET1586 [Dehalococcoides ethenogenes 195]618.8021290UnknownSP, TM
(135) gi∣29377408HypotheticalEF2944 [Enterococcus faecalis V583]584.9919312Unknownn, n
(136) gi∣15597823HypotheticalPA2627 [P. aeruginosa PAO1]5710.3523048Unknownn, n
(137) gi∣116750341HypotheticalSfum_2918 [Syntrophobacter fumaroxidans MPOB]545.4089798Carbohydrate bindingSP, TM
(138) gi∣167751139Hypothetical EUBSIR_02124 [Eubacterium siraeum DSM 15702]535.5044267Metal ion bindingn, TM
(139) gi∣26250264Hypotheticalc4442 [E. coli CFT073]539.3939090Unknownn, TM
(140) gi∣167754381Hypothetical ALIPUT_02675 [Alistipes putredinis DSM 17216]536.8918845Methyltransferase activityn, n
(141) gi∣116048834Hypothetical PA14_52490 [P. aeruginosa UCBPP-PA14]526.1917828Unknownn, n
(142) gi∣83312716Hypothetical amb3617 [Magnetospirillum magneticum AMB-1]525.4289219Cyclic nucleotide biosynthetic processn, TM
(143) gi∣154503183Hypothetical RUMGNA_01007 [Ruminococcus gnavus ATCC 29149]515.2949010Rhamnose metabolic processn, n
(144) gi∣15598505Hypothetical PA3309 [P. aeruginosa PAO1]515.5016486Response to stressn, n
(145) gi∣148255416HypotheticalBBta_4029 [Bradyrhizobium sp. BTAi1]514.224004Unknownn, n

TM: transmembrane domains; SP: signal peptide. pI: isoelectric point.

Table 2

The common OMV proteins.

Protein access IDProtein descriptionScorepIMassPredicted functionsMembrane domains
(75) gi∣576779GroEL [P. aeruginosa]7845.0457036Protein foldingn, n
(76) gi∣16785590850S ribosomal protein L28 [Haemophilus parasuis 29755]2424.9057645Protein synthesisn, n
(77) gi∣15596780Succinate dehydrogenase flavoprotein subunit [P. aeruginosa PAO1]1756.0463492Tricarboxylic acid cyclen, TM
(78) gi∣15596974OprF precursor [P. aeruginosa PAO1]1664.9837616Major porin, ion transportSP, TM
(79) gi∣15596375OprH precursor [P. aeruginosa PAO1]1079.0021561Response to Mg2+ starvationSP, TM
(80) gi∣15598888OMP precursor [P. aeruginosa PAO1]1039.4528497OMSP, TM
(81) gi∣2626833Chemotactic transducer [P. aeruginosaPAO1]984.8868395ChemotaxisSP, TM
(82) gi∣15599262OprG precursor [P. aeruginosa PAO1]934.8525178OmpW familySP, TM
(83) gi∣15598278Glycine betaine transmethylase [P. aeruginosa PAO1]744.7471360Utilization of choline and glycine betaine as carbon and nitrogen sourcesSP, TM
(84) gi∣15596750Cytochrome c oxidase subunit [P. aeruginosa PAO1]747.7922744Electron carrier activityn. TM
(85) gi∣37522034Glycosyltransferase [Gloeobacter violaceus PCC 7421]708.9647611Biosynthesis of glycoproteinsn, n
(86) gi∣15596166TolQ [P. aeruginosa PAO1]675.9625266Import of group A colicins for envelope integrityn, TM
(87) gi∣15599941 SecG [P. aeruginosa PAO1]655.2113199Protein translocationn, TM
(88) gi∣151545RNA polymerase subunit [P. aeruginosa]634.9530372RNA synthesisn, n
(89) gi∣115523809OmpA/MotB domain-containing protein [RhodoP. palustris BisA53]637.6045685Major nonspecific porinSP, TM
(90) gi∣114563330Phosphoglucomutase [Shewanella frigidimarina NCIMB 400]625.3962288Carbohydrate metabolic processn, n
(91) gi∣15596170OprL precursor [P. aeruginosa PAO1]615.9517914Peptidoglycan-associated OM lipoproteinSP, TM
(92) gi∣15598193Na(+)-translocating NADH-quinone reductase subunit C [P. aeruginosa PAO1]615.6727763Reduction of ubiquinone-1 to ubiquinol and transport of Na+ ionsSP, TM
(93) gi∣15598107TonB-dependent receptor, putative [P. aeruginosa PAO1]606.2480241High-affinity binding and energy-dependent uptake of specific substrates into the periplasmic spaceSP, TM
(94) gi∣162455126Protein kinase [Sorangium cellulosum So ce 56]576.16189825Kinase activityn, n
(95) gi∣15597002Peptidyl-prolyl cis-trans isomerase D [P. aeruginosa PAO1]574.9968699Protein foldingn, TM
(96) gi∣183602700Site-specific DNA-methyltransferase [Bifidobacterium animalis subsp. lactis HN019]566.2451123DNA methylationn, n
(97) gi∣15600134HflC [P. aeruginosa PAO1]509.4833095Peptidase activitySP, TM
(98) gi∣15599627Iron-sulfur protein [P. aeruginosa PAO1]506.0720815Iron-sulfur cluster assemblyn, n
(99) gi∣15595268Hypothetica PA0070 [P. aeruginosa PAO1]1148.9331697UnknownSP, TM
(100) gi∣15596030Hypothetica PA0833 [P. aeruginosa PAO1]1048.8924698OmpA familySP, TM
(101) gi∣15597431Hypothetica PA2235 [P. aeruginosa PAO1]935.9974519Lipopolysaccharide biosynthetic processn, TM
(102) gi∣15595823Hypothetica PA0626 [P. aeruginosa PAO1]879.6731273Unknownn, n
(103) gi∣15599828Hypothetica PA4632 [P. aeruginosa PAO1]816.9729141ProteolysisSP, TM
(104) gi∣15599183Hypothetica PA3988 [P. aeruginosa PAO1]675.2322870OM assemblySP, TM
(105) gi∣152989513Hypothetica PSPA7_0777 [P. aeruginosa PA7]624.7717484Unknownn, n
(106) gi∣15595830Hypothetica PA0633 [P. aeruginosa PAO1]624.9317528Unknownn, n
(107) gi∣15595812Hypothetica PA0615 [P. aeruginosa PAO1]604.5318939Unknownn, n
(108) gi∣15595813Hypothetica PA0616 [P. aeruginosa PAO1]585.9319410Unknownn, TM
(109) gi∣15599619Hypothetica PA4423 [P. aeruginosa PAO1]516.6965589UnknownSP, TM

TM: transmembrane domains; SP: signal peptide. pI: isoelectric point.

Interestingly, the OMV subproteomes seem to reflect the physiology of the cells under the antibiotic treatment and the cytotoxicity of OMVs to host cells. For instance, the known SOS-regulated proteins, such as FtsK (no. 41) [53] and catalase (no. 22) [54], were detected in the OMVs from the treated wild-type cells where SOS is induced. Proteins of efflux (no. 17) and cell motility (nos. 3, 34, and 42) were also found. Since efflux and cell mobility are involved in antibiotic resistance [55, 56], the presence of the related proteins in OMVs is likely to result from a response of the bacterial cells to the ciprofloxacin treatment. Furthermore, virulent proteins were detected in OMVs. In fact, cell mobility as mentioned above is known to enhance production of virulence factors [55]. An example in the WT OMV proteins is M48 family peptidase (no. 16 in Table 1) that contains Pseudomonas metalloproteases, elastase, and alkaline protease. These proteins are believed to mediate tissue penetration [57-59]. The examples in the common category include cytochrome c (no. 84 in Table 2) cytotoxic to macrophage [60], and OprG (no. 82) contributing to cytotoxicity toward human bronchial epithelial cells [61]. Examples in the lexAN group are the following: ATP-utilizing enzymes such as ATPase (no. 120 of Table 3) cytotoxic to macrophage [60] and the LysM domain carrying protein (no. 118) involved in pathogenesis [62]. Taken together, the OMV subproteomic results appeared aligned with the functional results pertinent to drug resistance, SOS, and cytotoxicity.

4. Discussion

Vesiculation from P. aeruginosa under ciprofloxacin treatment was investigated with multiple approaches. OMVs were isolated from the wild-type strain in which SOS is induced by ciprofloxacin and from the lexAN strain in which SOS is repressed. Cell morphology after the treatment showed cell filamentation, confirming SOS, while OMVs were not changed significantly in size during SOS. Vesiculation as determined chemically by the OMV protein and lipid levels and functionally by cytotoxicity is stimulated by the drug treatment, higher in the wild-type strain but suppressed in the lexAN strain. The overall increases for the wild-type and the lexAN strains suggest that the stimulation is attributed by the SOS-related and the independent factors; the suppression of further increase in the lexAN strain suggests that the additional augmentation involves SOS. The cytotoxicity of OMVs and the bacterial physiology under the antibiotic treatment and SOS were reflected by the results of the OMV subproteomic analysis. An intriguing observation is the presence of cytosolic proteins in OMVs. Considering the hydrophobic nature of outer membrane, we were tempted to suspect contamination of OMVs with the cytosolic proteins. Nevertheless, the presence of the cytosolic proteins in OMVs is not just coincidental but consistently documented [63]. In fact, GroEL (no. 75), ribosomal proteins (nos. 76, 121, and 124), and DNA binding proteins (no. 96, 115) were detected in outer membrane [52, 64–66] and OMV fractions [52, 67]. The possible mechanisms for their OMV inclusion may involve association of the cytoplasmic proteins with membrane proteins that may bring the former to membrane proximity. For example, peptidyl-prolyl cis-trans isomerase, a membrane-associated protein (no. 95 in Table 2), is a trigger factor that is highly conserved in most bacteria [68, 69]. The presence of the trigger factor in the stressed cells is reasonable as the trigger factor is generally believed to play a central role in bacterial survival of environmental insult. Since the trigger factor in E. coli is associated with the 50S ribosomal subunit [70] and GroEL [71-73], the factor is likely to be translocated with 50S ribosomal protein L28 and GroEL to OMVs. Besides, because OMVs can package DNA [48, 74] and P. aeruginosa OMVs carry DNA [75], the DNA binding proteins, such as DNA-binding stress protein (no. 115) and DNA-methyltransferase (no. 96), may be delivered into OMVs through hitching onto DNA. The molecular mechanisms behind the vesiculation stimulation during SOS remain poorly understood. OMVs are generated from living cells by budding from outer membrane bulges with subsequent fission [6, 7, 48, 74, 76]. Vesiculation does not concur with cell lysis, for OMVs package newly synthesized proteins [77-79]. These may be the reasons that OMV yields were too low when ciprofloxacin was used at and above MBC (data not shown), but the OMV levels were high when the drug was administered at 1 μg/mL. Therefore, the increase in the OMV protein levels observed in this work from the cultures treated with ciprofloxacin at 1 μg/mL is unlikely to result from cell lysis, especially as lysed cells barely were observed in the culture treated with the drug. The OMV protein levels are most likely to reflect the vesiculation stimulation during SOS. Indeed, the SOS-induced vesiculation is corroborated by the OMV lipid quantification. The OMV induction can be interpreted by combination of cell division delay and envelope alteration incurred in SOS. During SOS, sulA is induced, whose product inhibits and delays cell division transiently until DNA damage is ameliorated. In E. coli, this is achieved by SulA binding to FtsZ to block septum formation [42, 43, 80, 81]; similarly, a complex of P. aeruginosa SulA with FtsZ has been reported [82]. Inhibition of cell division was observed in P. aeruginosa treated with ciprofloxacin (Figure 2). According to the model of OMV biogenesis [28], such an episode of division inhibition may invoke temporary impact on the envelope structure, stimulating OMV generation. Our finding of vesiculation stimulation during SOS is highly significant. On one hand, suppression of the SOS-repair network by LexA in E. coli with engineered bacteriophage increased bactericidal effects of SOS-inducing antibiotics in vitro and enhanced survival of infected mice in vivo [83], paving a way for the LexA-based therapeutic strategy. In parallel are our results that LexA represses OMV stimulation and cytotoxicity, yet the lexAN-based strategy fails to eliminate them (Figures 3 and 4), pointing to existence of LexA independent mechanisms. The OMV protein levels increased in the cultures of the ciprofloxacin-treated lexAN mutant; the noncleavable LexA even appeared to contribute to production of some OMV proteins (Figure 3(a) and Table 3). The observations lead to the SOS-independent mechanisms that demand future endeavor in investigation. On the other hand, SOS appears responsible for the antibiotic inducible-biofilm formation [30, 40] and vesiculation though the mechanisms behind the induction seem a mystery. Our data obtained with the OMV protein-, the lipid-, the cell- and the proteomic-based approaches suggest that SOS plays a role in the antibiotic-stimulated vesiculation and in OMV-mediated cytotoxicity to macrophage. The result may help develop guidelines for antibiotic practice to prevent such side effects as vesiculation and the related cytotoxicity to host defense cells.
  82 in total

Review 1.  Structures of gram-negative cell walls and their derived membrane vesicles.

Authors:  T J Beveridge
Journal:  J Bacteriol       Date:  1999-08       Impact factor: 3.490

2.  Crystal structure of the SOS cell division inhibitor SulA and in complex with FtsZ.

Authors:  Suzanne C Cordell; Elva J H Robinson; Jan Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

3.  Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant.

Authors:  Jeannette N Williams; Paul J Skipp; Holly E Humphries; Myron Christodoulides; C David O'Connor; John E Heckels
Journal:  Infect Immun       Date:  2006-12-11       Impact factor: 3.441

4.  Comparative proteomic analysis of the Haemophilus ducreyi porin-deficient mutant 35000HP::P2AB.

Authors:  Jeremiah J Davie; Anthony A Campagnari
Journal:  J Bacteriol       Date:  2008-12-19       Impact factor: 3.490

Review 5.  LysM, a widely distributed protein motif for binding to (peptido)glycans.

Authors:  Girbe Buist; Anton Steen; Jan Kok; Oscar P Kuipers
Journal:  Mol Microbiol       Date:  2008-05       Impact factor: 3.501

6.  On the origin of membrane vesicles in gram-negative bacteria.

Authors:  L Zhou; R Srisatjaluk; D E Justus; R J Doyle
Journal:  FEMS Microbiol Lett       Date:  1998-06-15       Impact factor: 2.742

7.  Purification of outer membrane vesicles from Pseudomonas aeruginosa and their activation of an IL-8 response.

Authors:  Susanne J Bauman; Meta J Kuehn
Journal:  Microbes Infect       Date:  2006-06-05       Impact factor: 2.700

8.  Lipids of Salmonella typhimurium and Escherichia coli: structure and metabolism.

Authors:  G F Ames
Journal:  J Bacteriol       Date:  1968-03       Impact factor: 3.490

9.  Both leukotoxin and poly-N-acetylglucosamine surface polysaccharide protect Aggregatibacter actinomycetemcomitans cells from macrophage killing.

Authors:  Vishwanath Venketaraman; Albert K Lin; Amy Le; Scott C Kachlany; Nancy D Connell; Jeffrey B Kaplan
Journal:  Microb Pathog       Date:  2008-06-05       Impact factor: 3.738

10.  Virulence factors are released from Pseudomonas aeruginosa in association with membrane vesicles during normal growth and exposure to gentamicin: a novel mechanism of enzyme secretion.

Authors:  J L Kadurugamuwa; T J Beveridge
Journal:  J Bacteriol       Date:  1995-07       Impact factor: 3.490

View more
  45 in total

Review 1.  Outer membrane vesicles for vaccination and targeted drug delivery.

Authors:  Sihan Wang; Jin Gao; Zhenjia Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

2.  Antibiotic-Mediated Modulations of Outer Membrane Vesicles in Enterohemorrhagic Escherichia coli O104:H4 and O157:H7.

Authors:  Andreas Bauwens; Lisa Kunsmann; Helge Karch; Alexander Mellmann; Martina Bielaszewska
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 3.  Extracellular vesicles for nucleic acid delivery: progress and prospects for safe RNA-based gene therapy.

Authors:  L Jiang; P Vader; R M Schiffelers
Journal:  Gene Ther       Date:  2017-01-31       Impact factor: 5.250

Review 4.  Extracellular membrane vesicles in the three domains of life and beyond.

Authors:  Sukhvinder Gill; Ryan Catchpole; Patrick Forterre
Journal:  FEMS Microbiol Rev       Date:  2019-05-01       Impact factor: 16.408

5.  Extracellular vesicles of mycoplasmas and development of resistance to quinolones in bacteria.

Authors:  E S Medvedeva; N B Baranova; A A Mouzykantov; T Y Grigoreva; M N Davydova; O A Chernova; V M Chernov
Journal:  Dokl Biochem Biophys       Date:  2014-03-16       Impact factor: 0.788

Review 6.  Versatile effects of bacterium-released membrane vesicles on mammalian cells and infectious/inflammatory diseases.

Authors:  You-Jiang Yu; Xiao-Hong Wang; Guo-Chang Fan
Journal:  Acta Pharmacol Sin       Date:  2017-08-31       Impact factor: 6.150

7.  Epoxide-mediated differential packaging of Cif and other virulence factors into outer membrane vesicles.

Authors:  Alicia E Ballok; Laura M Filkins; Jennifer M Bomberger; Bruce A Stanton; George A O'Toole
Journal:  J Bacteriol       Date:  2014-08-11       Impact factor: 3.490

8.  Outer Membrane Vesicles Facilitate Trafficking of the Hydrophobic Signaling Molecule CAI-1 between Vibrio harveyi Cells.

Authors:  Sophie Brameyer; Laure Plener; Axel Müller; Andreas Klingl; Gerhard Wanner; Kirsten Jung
Journal:  J Bacteriol       Date:  2018-07-10       Impact factor: 3.490

9.  Identification and characterization of outer membrane vesicle-associated proteins in Salmonella enterica serovar Typhimurium.

Authors:  Jaewoo Bai; Seul I Kim; Sangryeol Ryu; Hyunjin Yoon
Journal:  Infect Immun       Date:  2014-06-16       Impact factor: 3.441

Review 10.  Environmentally controlled bacterial vesicle-mediated export.

Authors:  Nichole Orench-Rivera; Meta J Kuehn
Journal:  Cell Microbiol       Date:  2016-11       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.